No Effect of Red Clover–Derived Isoflavone Intervention on the Insulin-Like Growth Factor System in Women at Increased Risk of Colorectal Cancer

Background: Increased insulin-like growth factor (IGF)-I and IGF-II concentrations are related to increased colorectal cancer risk. Isoflavones have been associated with reduced colorectal cancer risk, and may affect the IGF system because of their weak estrogenic activity. The aim of the study was to investigate the effect of isolated isoflavones on serum concentrations of IGF system components. Materials and Methods: We conducted a randomized, placebo-controlled, double-blinded, crossover trial in four hospitals in the Netherlands to investigate the effect of an 8-week supplementation with red clover–derived isoflavones (84 mg/d) on serum IGF-I concentrations. In addition, serum concentrations of IGF-II and IGF binding proteins (IGFBP)-1, IGFBP-2, and IGFBP-3 were assessed. Normal colorectal tissue biopsies were obtained after the first intervention period and mRNA expression of IGF-I, IGF-II, IGFBP-3, and IGF-IR was evaluated. Our study population consisted of 34 postmenopausal women with a family history of colorectal cancer or a personal history of colorectal adenomas. Results: Isoflavone supplementation did not significantly affect serum concentrations of total IGF-I (mean relative within-person difference; IGF-I, −2.0%; 95% confidence interval, −8.0% to 3.9%). IGF-II and IGFBPs were also not significantly altered after isoflavone supplementation. Colorectal tissue mRNA expression of IGF system components did not significantly differ between individuals on isoflavone supplementation and those who received placebo. Conclusions: The results of our trial, supported by a qualitative review of soy trials published to date, suggest that isoflavones do not significantly affect circulating levels of IGF system components. Increased levels of IGF-I, as observed in most of these trials, are likely due to simultaneous protein supplementation. (Cancer Epidemiol Biomarkers Prev 2008;17(10):2585–93)

[1]  D. Voskuil,et al.  Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[2]  P. Carroll,et al.  Relationship of Dietary Protein and Soy Isoflavones to Serum IGF-1 and IGF Binding Proteins in the Prostate Cancer Lifestyle Trial , 2007, Nutrition and cancer.

[3]  L. V. van't Veer,et al.  Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. , 2007, The Journal of nutrition.

[4]  Yoko Takahashi,et al.  Molecular signatures of soy‐derived phytochemicals in androgen‐responsive prostate cancer cells: A comparison study using DNA microarray , 2006, Molecular Carcinogenesis.

[5]  N. Wald,et al.  Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies , 2006, British Journal of Cancer.

[6]  A. Leathem,et al.  Short-term phytoestrogen supplementation alters insulin-like growth factor profile but not lipid or antioxidant status. , 2006, The Journal of nutritional biochemistry.

[7]  E. Kim,et al.  Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. , 2005, Journal of medicinal food.

[8]  W. Leung,et al.  Increasing incidence of colorectal cancer in Asia: implications for screening. , 2005, The Lancet. Oncology.

[9]  G. Maskarinec,et al.  Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women , 2005, British Journal of Nutrition.

[10]  J. Potter,et al.  Soy protein containing isoflavones does not decrease colorectal epithelial cell proliferation in a randomized controlled trial. , 2005, The American journal of clinical nutrition.

[11]  S. Gapstur,et al.  Sequential, randomized trial of a low‐fat, high‐fiber diet and soy supplementation: Effects on circulating IGF‐I and its binding proteins in premenopausal women , 2005, International journal of cancer.

[12]  S. Hankinson,et al.  A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[13]  M. Payton,et al.  One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women , 2005, Nutrition journal.

[14]  E. Kallay,et al.  Phytoestrogens and colorectal cancer prevention. , 2005, Vitamins and hormones.

[15]  L. V. van't Veer,et al.  The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  Yoko Takahashi,et al.  Using DNA microarray analyses to elucidate the effects of genistein in androgen‐responsive prostate cancer cells: Identification of novel targets , 2004, Molecular carcinogenesis.

[17]  M. Cazzaniga,et al.  A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers , 2004, Clinical Cancer Research.

[18]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[19]  D. Voskuil,et al.  Insulin-Like Growth Factor (IGF)-System mRNA Quantities in Normal and Tumor Breast Tissue of Women with Sporadic and Familial Breast Cancer Risk , 2004, Breast Cancer Research and Treatment.

[20]  J. Woodside,et al.  Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study , 2004, European Journal of Clinical Nutrition.

[21]  G. Blackburn,et al.  Combined inhibition of estrogen‐dependent human breast carcinoma by soy and tea bioactive components in mice , 2004, International journal of cancer.

[22]  M. Banerjee,et al.  Soy Isoflavones in the Treatment of Prostate Cancer , 2003, Nutrition and cancer.

[23]  C. Mantzoros,et al.  Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Potter,et al.  Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial. , 2003, The Journal of nutrition.

[25]  H. Adlercreutz,et al.  Time-resolved fluoroimmunoassay for equol in plasma and urine , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  M. Payton,et al.  Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  K. Setchell,et al.  The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. , 2002, The Journal of nutrition.

[28]  M. Payton,et al.  Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. , 2002, The Journal of nutrition.

[29]  Heidi D Nelson,et al.  Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.

[30]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[31]  A. Neugut,et al.  Risk factors for advanced colorectal adenomas: a pooled analysis. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  L. Howes,et al.  Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense). , 2002, Journal of alternative and complementary medicine.

[33]  F. al-Azzawi,et al.  Estrogen and colon cancer:current issues , 2002, Climacteric : the journal of the International Menopause Society.

[34]  B. Hollis,et al.  Soy Protein: Its Effects on Intestinal Calcium Transport, Serum Vitamin D, and Insulin-like Growth Factor-I in Ovariectomized Rats , 2002, Calcified Tissue International.

[35]  H. Aukema,et al.  Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. , 2001, Kidney international.

[36]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[37]  R. Marcus,et al.  Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[39]  S. Oparil,et al.  Dietary changes favorably affect bone remodeling in older adults. , 1999, Journal of the American Dietetic Association.

[40]  G. Blackburn,et al.  Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. , 1999, The Journal of nutrition.

[41]  K. Setchell,et al.  Dietary isoflavones: biological effects and relevance to human health. , 1999, The Journal of nutrition.

[42]  B. Bonanni,et al.  Biologic activity of tamoxifen at low doses in healthy women. , 1998, Journal of the National Cancer Institute.

[43]  W. Mazur,et al.  Phyto-oestrogens and Western diseases. , 1997, Annals of medicine.

[44]  J. Ketelslegers,et al.  Nutritional regulation of insulin-like growth factor-I. , 1995, Metabolism: clinical and experimental.

[45]  C. Rosen,et al.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[47]  K. Ho,et al.  Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[48]  M. Hills,et al.  The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.